Expedition Medicines

#### Potential areas of differentiation - If the company’s proteome-wide covalent interaction mapping is reproducible and scalable, it could provide datasets that support learning binding rules for shallow protein surfaces and other difficult target classes. - Leadership experience drawn from organizations active in covalent chemistry and chemoproteomics may be operationally important. #### Areas where alternatives may be stronger - Frontier Medicines and Vividion (Bayer) have more established public positioning in chemoproteomics-driven covalent discovery and a longer public track record. - Schrödinger provides mature computational chemistry workflows and enterprise deployment practices that are often easier to benchmark in procurement processes. - Insilico and Recursion have more extensive public records of partnerships and some published milestones that buyers can use in diligence, although outcomes across the industry remain heterogeneous. #### Adoption trends - Investment and deal activity in AI-enabled discovery continue, but buyer skepticism has increased, with greater emphasis on clinical proof and independently verifiable performance metrics rather than platform claims alone.